… Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets Agreement provides ProQR with … divest its late stage ophthalmic assets, sepofarsen and ultevursen, to Théa. Under the terms of the agreement, ProQR …
… Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets Divestment of sepofarsen and … divesting late stage ophthalmic assets, sepofarsen and ultevursen, to Laboratoires Théa (Théa). “Following previous …
ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that Company management will pres
… and Financial Results Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic … divest its late-stage ophthalmic assets, sepofarsen and ultevursen, to Théa . Under the terms of the agreement, ProQR …
… in Q2 2022 Phase 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome and retinitis … anticipate sharing data from our Helia extension trial of ultevursen, as well as the initial data from our QR-504a …